InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 207 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... January 24, 2022 For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining May 25, 2021 Cancer in My Community: Overcoming Delays in Care for Children With... July 6, 2023 A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most... May 15, 2020 Load more HOT NEWS Cancer in My Community: How People With Cancer Access Care in... New Technology System Allows Patients To Get A Mammogram And Biopsy... ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ A College Senior vs. A Global Pandemic
